1. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets
Yin HU ; Dandan YANG ; Yichao XU ; Rong SHAO ; Zourong RUAN ; Bo JIANG ; Jinliang CHEN ; Honggang LOU
Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(1):63-69
AIM: To evaluate the bioequivalence of two candesartan cilexetil tablet formulations in healthy Chinese subjects after administration of a single dose, and an artificial neural network model was established to predict the candesartan plasma concentration, and provide a basis for clinical rational use of drugs. METHODS: Thirty-two healthy Chinese subjects were enrolled for oral administration of a single 8 mg dose of candesartan cilexetil tablet (test or reference product) under fasting or fed conditions to conduct a bioequivalence study. The bioequivalence results were used to build a back-propagation artificial neural network model by MATLAB software, and the model was internally and externally verified to predict the plasma concentration. RESULTS: Under both fasting and fed conditions, the C
2.Effectiveness, safety and cost of urinary follicle stimulating hormone in controlled ovarian stimulation in China: multi-center retrospective cohort study of 102 061 in vitro fertilization cycles
Yimin ZHU ; Yue GAO ; Donghong NAI ; Linli HU ; Lei JIN ; Ying ZHONG ; Ze WU ; Guimin HAO ; Qiongfang WU ; Yichun GUAN ; Hong JIANG ; Cuilian ZHANG ; Minli LIU ; Xiaohong WANG ; Xiaoming TENG ; Jinliang DUAN ; Liran LI ; Yue ZHANG ; Hong YE
Chinese Journal of Obstetrics and Gynecology 2022;57(7):510-518
Objective:To explore the effectiveness, safety and cost between urinary follicle stimulating hormone (uFSH) and recombinant follicle stimulating hormone (rFSH) in controlled ovarian stimulation (COS) in China.Methods:Data were collected from 16 reproductive centers in China covering oocytes collection time from May 1, 2015 to June 30, 2018. Eligible patients were over 18 years old, adopting COS with uFSH (uFSH group) or rFSH (rFSH group) as start gonadotropins (Gn), and using in vitro fertilization (IVF) and (or) intracytoplasmic sperm injection for fertilisation, excluding frozen embryo recovery cycle. Generalised estimating equation was used to address the violation of independency assumption between cycles due to multiple IVF cycles for one person and clustering nature of cycles carried out within one center. Controlling variables included age, body mass index, anti-Müllerian hormone level, cause of infertility, ovulation protocol, type of fertilisation, number of embryos transferred, number of days of Gn use.Results:Totally 102 061 cycles met eligibility criteria and were included in the analyses. In terms of effectiveness, after controlling relevant unbalanced baseline characteristics, compared with rFSH group, the high oocyte retrieval (>15 oocytes was considered high retrieval) rate of uFSH group significantly decreased in gonadotropin-releasing hormone agonist protocol ( OR=0.642, P<0.01) and in gonadotropin-releasing hormone antagonist protocol ( OR=0.556, P=0.001), but the clinical pregnancy rate per transfer cycle and the live birth rate per transfer cycle significantly increased ( OR=1.179, OR=1.169, both P<0.01) in both agonist and antagonist protocols. For safety, multiple analysis result demonstrated that in the agonist protocol, compared with rFSH group, the incidence of moderate to severe ovarian hyperstimulation syndrome of uFSH group significantly decreased ( OR=0.644, P=0.002). The differences in ectopic pregnancy rate and multiple pregnancy rate between the uFSH and rFSH groups were not significant ( P=0.890, P=0.470) in all patients. In terms of cost, compared with rFSH group, the uFSH group had lower total Gn costs for each patient ( P<0.01). Conclusion:For patients who underwent COS, uFSH has better safety, and economic profiles over rFSH in China.
3.Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody.
Fang LI ; Meng LUO ; Wenyang ZHOU ; Jinliang LI ; Xiyun JIN ; Zhaochun XU ; Liran JUAN ; Zheng ZHANG ; Yuou LI ; Renqiang LIU ; Yiqun LI ; Chang XU ; Kexin MA ; Huimin CAO ; Jingwei WANG ; Pingping WANG ; Zhigao BU ; Qinghua JIANG
Protein & Cell 2021;12(10):751-755
4.Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.
Li NI ; Zheng WEN ; Xiaowen HU ; Wei TANG ; Haisheng WANG ; Ling ZHOU ; Lujin WU ; Hong WANG ; Chang XU ; Xizhen XU ; Zhichao XIAO ; Zongzhe LI ; Chene LI ; Yujian LIU ; Jialin DUAN ; Chen CHEN ; Dan LI ; Runhua ZHANG ; Jinliang LI ; Yongxiang YI ; Wei HUANG ; Yanyan CHEN ; Jianping ZHAO ; Jianping ZUO ; Jianping WENG ; Hualiang JIANG ; Dao Wen WANG
Frontiers of Medicine 2021;15(5):704-717
We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, P = 0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), -46.39 (-86.83 to -5.94) HU; P = 0.025) and day 14 (mean difference (95% CI), -74.21 (-133.35 to -15.08) HU; P = 0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.
COVID-19
;
Humans
;
Medicine, Chinese Traditional
;
Research
;
SARS-CoV-2
;
Treatment Outcome
5. Bioequivalence of norfloxacin tablets in Chinese Healthy volunteers under Fasting and Fed Condition
Dandan YANG ; Jinliang CHEN ; Honggang LOU ; Zourong RUAN ; Bo JIANG ; Jinlian WU ; Jing CHEN
Chinese Journal of Clinical Pharmacology and Therapeutics 2020;25(12):1357-1362
AIM: To compare the bioavailability of norfloxacin tablets produced by Zhejiang Pharmaceutical Co., Ltd with the original product BACCIDAL, and to evaluate bioequivalence of two formulations, a randomized, open, two-cycle, self-crossing trial in healthy Chinese population was designed. METHODS: Under fasting and fed conditions, healthy volunteers were given a single dose of norfloxacin test or reference tablets for 100 mg. Liquid chromatography-mass spectrometry (LC-MS/MS) method were used to determine drug concentration in the plasma taken at different time points before and after dosing. Pharmacokinetic parameters and the bioequivalence of the two formulations were calculated by WinNonlin 7.0 software. RESULTS: A total of 28 healthy volunteers were enrolled and completed the fasting test. The pharmacokinetic parameters for test and reference preparations in fasting state were as follows: C
6. Molecular epidemiology analysis of Brucella in ticks in Xinjiang Uygur Autonomous Region
Mengmeng JIANG ; Meihua YANG ; Ruixia SONG ; Yuanzhi WANG ; Jinliang SHENG
Chinese Journal of Endemiology 2019;38(12):947-950
Objective:
To carry out a investigation on molecular epidemiological features of tick-borne
7. Major findings from the 4th Evaluation of the National Healthcare Improvement Initiative
Jing SUN ; Feng JIANG ; Linlin HU ; Yu JIANG ; Jing MA ; Li LUO ; Ying MAO ; Guo ZHANG ; Jinliang HU ; Bingjie SHEN ; Yinuo WU ; Peiwen ZHANG ; Jialin JI ; Ran GUO ; Meicen LIU ; Shichao WU ; Shiyang LIU ; Zijuan WANG ; Yuanli LIU
Chinese Journal of Hospital Administration 2019;35(9):705-711
Objective:
To carry out the 4th round of third-party evaluation on the implementation and effect of the 1st year of the 2nd Phase National Healthcare Improvement Initiative(abbreviated as Initiative)since 2015.
Methods:
The 4th round of the evaluation survey adopted the same methods, organization and execution, and technical roadmap as the former three rounds of evaluations.
Results:
The 4th round of evaluation was carried out from 18 March to 9 April, 2019 at 185 public hospitals in 31 provinces(autonomous regions, municipalities directly under the Central Government)and Xinjiang Production and Construction Corps.Facility survey, health professional survey and patient survey were conducted at each of the sample health facilities. A total of 120 782 valid questionnaires were collected from 144 non-psychiatric health facilities, 16 246 valid questionnaires were obtained from 41 psychiatric health facilities, and 252 cases of outstanding departments/hospitals in healthcare improvement were also collected. The average overall scoring of the 12 dimensions to assess Initiative implementation at 144 non-psychiatric health facilities was 84.4%. The overall outpatient satisfaction scoring was 91.1%, 96.7%for the inpatients. The overall inpatient satisfaction(family members inclusive) at 41 psychiatric health facilities was 93%. Areas remaining to be improved include day-surgery, telemedicine and medical social work. Compared with technical services, non-technical care should be further strengthened. The compensation, workload and work environment of the healthcare providers are still to be improved.
Conclusions
The implementation of the Initiative by health facilities has been greatly improved. The percentage of health facilities and patients who had positive perceptions of improved doctor-patient relationship has been increasing. Patient care experiences at public hospitals have been generally improved, and the implementation of promoting traditional Chinese Medicine practices also made progress. However, work satisfaction of healthcare providers was found to be rather low, compared to the high level of patient satisfaction.
8. Analysis of respiratory viruses in children with acute respiratory tract infection in Weifang
Huafang JIANG ; Jinliang LI ; Li LI ; Yuanyuan WANG ; Wenning HAN
Chinese Journal of Experimental and Clinical Virology 2018;32(3):272-276
Objective:
To explore the viral pathogens in hospitalized children with acute respiratory tract infection in Weifang.
Methods:
Nasopharyngeal secretion (NPS) samples were collected from hospitalized patients with acute respiratory tract infection from July 2016 to June 2017. The NPS samples were detected for 16 respiratory virus types/subtypes including influenza A virus (FluA), influenza B virus (FluB), seasonal influenza A HlNl virus (sH1N1), parainfluenza virus types 1, 2 and 3 (PIV-1, 2, 3), respiratory syncytial virus A (RSVA), respiratory syncytial virus B (RSVB), human rhinovirus (HRV), adenovirus (ADV), human metapneumovirus (HMPV), four coronavirus sybtypes (Cov-NL63, 229E, OC43, HKUl) and human bocavirus (BoV) by multiplex reverse transcription polymerase chain reaction (RT-PCR) assays based on automatic capillary electrophoresis.
Results:
A total of 769 children with respiratory tract infection were enrolled, and the overall positive rate for the 16 common respiratory tract viruses was 33.68% (259/769). The positive rates were as follows: RSV (9.23%), PIV (7.93%), Flu (6.89%), HRV (4.68%), ADV (3.38%), HMPV (1.69%), CoV (0.91%), BoV (0.65%). The positive rate of viral detection showed significant differences among different age groups (
9.Prevention and treatment of laparoscopic cholecystectomy in patients with liver cirrhosis
Guiliang JIAO ; Zhilong JIANG ; Jinliang LU ; Zhirong CHENG ; Jianfeng XU ; Bin ZHOU ; Lai CHANG ; Kai LIU
Chinese Journal of Primary Medicine and Pharmacy 2017;24(14):2195-2198
Objective To explore the risk and treatment of laparoscopic cholecystectomy(LC) in patients with liver cirrhosis and cholelithiasis.Methods To summarize the clinical data of 28 patients with liver cirrhosis and cholelithiasis.The patients were repeated right upper quadrant pain,including 4 cases of gallbladder neck stones incarcerated,gallbladder effusion.Among them,there were 20 cases of hepatitis B cirrhosis,5 cases of schistosomiasis cirrhosis,3 cases of alcohol.Results There were 6 patients with hemorrhage during operation.Among them,5 patients were treated with gelatin sponge,hemostatic gauze and bio-glue spray to stop bleeding,1 case was transferred to open surgery because of bleeding.The remaining 27 cases of LC were successful.Complications occurred in 8 patients,3 cases of increased liver function abnormalities,1 case of upper gastrointestinal bleeding,1 case of mild hepatic encephalopathy,2 cases of significant ascites formation,1 patient underwent subtotal resection of the gallbladder with Hartmanns bag,and bile was found in the ascites after surgery,but the bile disappeared after five days.All patients with complications after symptomatic treatment were cured,no death,no major bleeding and liver failure,bile duct injury,severe biliary fistula and other serious complications.Conclusion Although the risk of LC in patients with liver cirrhosis is higher than that in the general population,with the help of current high-tech surgical instruments,we can safely accomplish this with an improved surgical procedure.As these patients require high technical requirements of surgery,surgeons must have a wealth of experience and familiar laparoscopic liver and gallbladder anatomy.
10.Using Coben analysis to evaluate the therapeutic effect of maxillary protraction on maxillary maldevelopment.
Jinliang ZHUANG ; Xun LI ; Yujun JIANG ; Shanshan XU ; Xiaohua DING ; Yuanping CHEN
West China Journal of Stomatology 2015;33(1):58-62
OBJECTIVEWe aims to evaluate the therapeutic effect of maxillary protraction on maxillary maldevelopment using Coben analysis to illustrate the advantages of Coben analysis in identifying pathogenic mechanisms and in designing treatment plans for Class III malocclusions.
METHODSA total of 120 patients were diagnosed to have skeletal Class I maloc- clusions with maxillary maldevelopment. These patients were selected as the subjects of the present research. Maxillary protraction was exerted to promote maxilla growth. Cephalometric analysis was conducted by using Coben analysis and angle analyses of Beijing Medical University to collect data before and after maxillary protraction.
RESULTSAccording to Coben analysis measurements, the height of facies cranii increased after maxillary protraction. The depth of lower face decreased, whereas that of mid-face increased and the Ptm-A value increased significantly in the mid-face (P < 0.001). In the angle ana- lysis of Beijing Medical University, SNA, ANB, U1/NA, U1/SN, MP/SN, and Y-axis angles increased significantly (P < 0.001), whereas SNB, U1/L1 (P < 0.001), and L1/MP (P < 0.05) decreased.
CONCLUSIONMaxillary protraction has a significant effect on growing skeletal Class III malocclusions withthe chief mechanism of Ptm-A value just diagnosed as minor by Coben analysis. Coben analysis is visual and clear in identifying pathogenic mechanisms of Class III malocclusions.
Cephalometry ; Face ; Humans ; Malocclusion, Angle Class III ; Maxilla

Result Analysis
Print
Save
E-mail